Prostaglandin E1 versus sildenafil in the management of erectile dysfunction.
- Author:
Zhen-Lin WANG
1
;
Bin LI
;
Jing-Zhong YAN
;
Sheng-Guo DONG
Author Information
- Publication Type:Clinical Trial
- MeSH: Administration, Oral; Adult; Aged; Alprostadil; therapeutic use; Drug Administration Routes; Erectile Dysfunction; drug therapy; Humans; Male; Middle Aged; Piperazines; therapeutic use; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome
- From: National Journal of Andrology 2002;8(3):198-200
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo evaluate the outcome of treatment in patients with erectile dysfunction (ED) using sildenafil or intracavernosal injection of prostaglandin E1(PGE1).
METHODS54 patients with ED were randomly classified into two groups and received either oral sildenafil (group A) or intracavernosal injection of PGE1(group B) for 4-9 months with an average of 6 months.
RESULTSThe percentages of efficacy in the two groups were 80.0% and 83.3%, respectively. There was no statistical difference between group A and B (P > 0.05). Two of six patients who did not respond to sildenafal in group A achieved erections sufficient for sexual intercourse when the six patients received intracavernous injection of PGE1. None of the four patients who did not respond to intracavernous injection of PEG1 in group B achieved erection sufficient for sexual intercourse when they received oral sildenafil.
CONCLUSIONSBoth oral sildenafil and intracavernous injection of PGE1 are effective for patients with ED of various etiologies. The patients who do not respond to sildenafil can receive intracavernous injection therapy. The satisfactory results can probably achieved.
